|1.||Bomalaski, John S: 9 articles (12/2013 - 04/2002)|
|2.||Schwaneberg, Ulrich: 8 articles (07/2015 - 03/2008)|
|3.||Ni, Ye: 8 articles (07/2015 - 03/2008)|
|4.||Zhu, Leilei: 7 articles (07/2015 - 06/2009)|
|5.||Clark, Mike A: 6 articles (01/2007 - 04/2002)|
|6.||Kung, Hsing-Jien: 5 articles (09/2014 - 10/2008)|
|7.||Bold, Richard J: 5 articles (09/2014 - 10/2008)|
|8.||Shen, Li-Jiuan: 5 articles (08/2014 - 03/2003)|
|9.||Savaraj, Niramol: 5 articles (11/2013 - 10/2005)|
|10.||Min, Bon-Hong: 5 articles (05/2009 - 11/2004)|
|1.||Melanoma (Melanoma, Malignant)
10/01/2009 - "Growth inhibition of human melanoma cells by a recombinant arginine deiminase expressed in Escherichia coli."
09/01/1992 - "High sensitivity of human melanoma cell lines to the growth inhibitory activity of mycoplasmal arginine deiminase in vitro."
12/01/2013 - "Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET."
09/20/2013 - "Arginine deiminase is a promising anticancer drug active against melanoma, hepatocarcinoma and other tumors. "
01/01/2013 - "Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma."
04/01/2011 - "Rapid evolution of arginine deiminase for improved anti-tumor activity."
07/17/2015 - "The principle of LiMEx was validated by evolving arginine deiminase (ADI, an anticancer therapeutic) for stronger inhibition of tumor growth. "
02/01/2015 - "PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from Pseudomonas plecoglossicida."
09/01/2014 - "To examine their property as solubility enhancers, aggregation-prone Mycoplasma arginine deiminase (mADI), which has been suggested as anti-cancer agent, was fused to the C-terminal of each of them and cloned into pET28a to be expressed in the E. "
06/01/2009 - "Expression of arginine deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and its anti-tumor activity."
|3.||Hepatocellular Carcinoma (Hepatoma)
09/01/2003 - "Regression of hepatocellular cancer in a patient treated with arginine deiminase."
03/01/2010 - "Recently, phase I and II clinical trials in patients with melanoma and hepatocellular carcinoma have shown the safety and efficacy of plasma arginine depletion by stabilized arginine deiminase. "
06/01/2011 - "Arginine deiminase (ADI), an arginine-degrading enzyme, has been used in the treatment of tumours sensitive to arginine deprivation, such as malignant melanoma (MM) and hepatocellular carcinoma (HCC). "
09/01/2003 - "We report the first pharmacokinetic and clinical response data from a patient with unresectable hepatocellular cancer treated with a new drug, ADI PEG20,000 mw (arginine deiminase-polyethylene glycol 20,000 molecular weight). "
04/01/2012 - "Arginine deiminase (ADI) has been studied as a potential anti-cancer agent for inhibiting arginine-auxotrophic tumors (such as melanomas and hepatocellular carcinomas) in phase III clinical trials. "
05/01/2000 - "Our results suggest the possibility of a future use of arginine deiminase for the therapy of leukemia."
02/01/1997 - "A growth-inhibitory substance found in the culture of a B-precursor leukemia cell line, NALM-20, was purified from the serum-free culture medium and identified as arginine deiminase derived from Mycoplasma arginini (EC 18.104.22.168). "
05/01/2000 - "We report here that the enzyme arginine deiminase is approximately 100-fold more potent than L-asparaginase in inhibiting the proliferation of cultured human lymphatic leukemia cell lines while it appears to be less effective in leukemia cells of myeloid origin. "
05/01/2000 - "Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis."
01/01/2001 - "Apoptotic effects of selected strains of lactic acid bacteria on a human T leukemia cell line are associated with bacterial arginine deiminase and/or sphingomyelinase activities."
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2014 - "The purpose of this study was to evaluate the therapeutic efficacy of arginine deiminase in combination with gemcitabine, the first line chemotherapeutic drug for patients with pancreatic cancer, and to identify the mechanisms associated with its anticancer effects. "
01/01/2014 - "We further tested the effects of the combination regimen of arginine deiminase with gemcitabine on pancreatic cancer cell lines in vitro and in vivo. "
01/01/2014 - "Our results suggest that arginine deprivation by arginine deiminase, in combination with gemcitabine, may offer a novel effective treatment strategy for patients with pancreatic cancer and potentially improve the outcome of patients with pancreatic cancer."
01/01/2014 - "Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling."
10/15/2008 - "Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase."
|3.||Phosphopyruvate Hydratase (Enolase)
|4.||Ornithine Carbamoyltransferase (Ornithine Transcarbamylase)
|6.||Staphylococcal Protein A (A, Protein)
|7.||Immunoglobulin A (IgA)
|10.||Argininosuccinate Synthase (Argininosuccinate Synthetase)
|1.||Heterologous Transplantation (Xenotransplantation)